These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 27525951)

  • 1. Target fishing of glycopentalone using integrated inverse docking and reverse pharmacophore mapping approach.
    Gurung AB; Ali MA; Bhattacharjee A; Al-Anazi KM; Farah MA; Al-Hemaid FM; Abou-Tarboush FM; Lee J; Kim SY; Al-Anazi FS
    Genet Mol Res; 2016 Aug; 15(3):. PubMed ID: 27525951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycopentalone, a novel compound from Glycosmis pentaphylla (Retz.) Correa with potent anti-hepatocellular carcinoma activity.
    Sreejith PS; Asha VV
    J Ethnopharmacol; 2015 Aug; 172():38-43. PubMed ID: 26068427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular docking of the anticancer bioactive compound proceraside with macromolecules involved in the cell cycle and DNA replication.
    Gurung AB; Ali MA; Bhattacharjee A; AbulFarah M; Al-Hemaid F; Abou-Tarboush FM; Al-Anazi KM; Al-Anazi FS; Lee J
    Genet Mol Res; 2016 May; 15(2):. PubMed ID: 27173346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular docking and dynamics simulation study of bioactive compounds from Ficus carica L. with important anticancer drug targets.
    Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM
    PLoS One; 2021; 16(7):e0254035. PubMed ID: 34260631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico insights into the identification of potential novel angiogenic inhibitors against human VEGFR-2: a new SAR-based hierarchical clustering approach.
    Konidala KK; Bommu UD; Pabbaraju N
    J Recept Signal Transduct Res; 2018 Aug; 38(4):372-383. PubMed ID: 30396316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.
    Li Y; Gao W; Li F; Wang J; Zhang J; Yang Y; Zhang S; Yang L
    Mol Biosyst; 2013 Sep; 9(9):2266-81. PubMed ID: 23864105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular dynamics simulation and free energy calculation studies of kinase inhibitors binding to active and inactive conformations of VEGFR-2.
    Wu X; Wan S; Wang G; Jin H; Li Z; Tian Y; Zhu Z; Zhang J
    J Mol Graph Model; 2015 Mar; 56():103-12. PubMed ID: 25594497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virtual screening studies to design potent CDK2-cyclin A inhibitors.
    Vadivelan S; Sinha BN; Irudayam SJ; Jagarlapudi SA
    J Chem Inf Model; 2007; 47(4):1526-35. PubMed ID: 17523616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploration for novel inhibitors showing back-to-front approach against VEGFR-2 kinase domain (4AG8) employing molecular docking mechanism and molecular dynamics simulations.
    Rampogu S; Baek A; Zeb A; Lee KW
    BMC Cancer; 2018 Mar; 18(1):264. PubMed ID: 29514608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular dynamic behavior and binding affinity of flavonoid analogues to the cyclin dependent kinase 6/cyclin D complex.
    Khuntawee W; Rungrotmongkol T; Hannongbua S
    J Chem Inf Model; 2012 Jan; 52(1):76-83. PubMed ID: 22172011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting malaria with specific CDK inhibitors.
    Geyer JA; Prigge ST; Waters NC
    Biochim Biophys Acta; 2005 Dec; 1754(1-2):160-70. PubMed ID: 16185941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study on Wangzaozin-A-Inducing Cancer Apoptosis and Its Theoretical Protein Targets.
    Chen J; Wang S; Lu X
    Technol Cancer Res Treat; 2016 Aug; 15(4):589-96. PubMed ID: 26082454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stepwise development of structure-activity relationship of diverse PARP-1 inhibitors through comparative and validated in silico modeling techniques and molecular dynamics simulation.
    Halder AK; Saha A; Saha KD; Jha T
    J Biomol Struct Dyn; 2015; 33(8):1756-79. PubMed ID: 25350685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification.
    Islam MA; Pillay TS
    J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring cyclin-dependent kinase inhibitors: a comprehensive study in search of CDK-6 inhibitors using a pharmacophore modelling and dynamics approach.
    Chagaleti BK; Saravanan V; Vellapandian C; Kathiravan MK
    RSC Adv; 2023 Nov; 13(48):33770-33785. PubMed ID: 38019988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations.
    Chohan TA; Chen JJ; Qian HY; Pan YL; Chen JZ
    Mol Biosyst; 2016 Apr; 12(4):1250-68. PubMed ID: 26883408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Dynamics Mechanisms of the Inhibitory Effects of Abemaciclib, Hymenialdisine, and Indirubin on CDK-6.
    Basati G; Saffari-Chaleshtori J; Abbaszadeh S; Asadi-Samani M; Ashrafi-Dehkordi K
    Curr Drug Res Rev; 2019; 11(2):135-141. PubMed ID: 31875784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of in silico models for pyrazoles and pyrimidine derivatives as cyclin-dependent kinase 2 inhibitors.
    Wang F; Ma Z; Li Y; Zhu S; Xiao Z; Zhang H; Wang Y
    J Mol Graph Model; 2011 Sep; 30():67-81. PubMed ID: 21763166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacophore modeling, virtual screening, docking and in silico ADMET analysis of protein kinase B (PKB β) inhibitors.
    Vyas VK; Ghate M; Goel A
    J Mol Graph Model; 2013 May; 42():17-25. PubMed ID: 23507201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First pharmacophore model of CCR3 receptor antagonists and its homology model-assisted, stepwise virtual screening.
    Jain V; Saravanan P; Arvind A; Mohan CG
    Chem Biol Drug Des; 2011 May; 77(5):373-87. PubMed ID: 21284830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.